The painful vaso-occlusive crisis is the most common event and principal cause of sickle cell disease morbidity, as well as the most frequent reason for seeking emergency care and hospital admission. This study aimed to assess the índications, doses, administration routes and side effects of analgesics recommended to treat painful crises in children. A literature search was done in the Medline, SciELO, Lilacs and PubMed databases using the following keywords: anemia, sickle cell, analgesia. pain and child. Analysis of the literature reveafed that the treatment of painful crisis in children is complex, as it involves the subjectivity of pain, its correct measurement and its restrictíon to medication that is safe and efficient for use in the pediatric population, Treatment protocols exist as general guidelines, as conduct should always be individualized, Successful pain treatment depends on knowíedge of the pathophysiology of painful crisis, pharmacology of analgesics and valuing what the patient is feeling. Physicians should be ready to recognize and treat this complication which has a relevant impact on the quality of life of children with sickle cell disease

Authors

  • Meire Aparecida Tostes
  • Josefina Aparecida Pellegrini Braga
  • Claudio Arnaldo Len

Keywords:

Analgesía, Sickle cell, Child, Pain

Abstract

The painful vaso-occlusive crisis is the most common event and principal cause of
sickle cell disease morbidity, as well as the most frequent reason for seeking emergency care and hospital admission. This study aimed to assess the índications, doses, administration routes and side effects of analgesics recommended to treat painful crises in children. A literature search was done in the Medline, SciELO, Lilacs and PubMed databases using the following keywords: anemia, sickle cell, analgesia. pain and child. Analysis of the literature reveafed that the treatment of painful crisis in children is complex, as it involves the subjectivity of pain, its correct measurement and its restrictíon to medication that is safe and efficient for use in
the pediatric population, Treatment protocols exist as general guidelines, as conduct should always be individualized, Successful pain treatment depends on knowíedge of the pathophysiology of painful crisis, pharmacology of analgesics and valuing what the patient is feeling. Physicians should be ready to recognize and treat this complication which has a relevant impact on the quality of life of children with sickIe cell disease.

Downloads

Download data is not yet available.

References

Dover GJ, Platt OS. Sickie cell disease. In: Nathan DG. Orkin SH. Nathan and Oski's hematology of infancy and childhood. 5th ed. Philadelphia: W.B. Saunders; 1998.

Zago MA. Considerações gerais. In: Agência Nacional de Vigilância Sanitária. Manual de diagnóstico e tratamento de doenças falciformes. Brasília: Anvisa; 2002.

Fixler J, Styles L. Sickle cell disease. Pediatr CIÉn North Am. 2002; 49(6):1193-210.

Erush K, Ware R. Kinney T. Emergency department visits by children with sickle hemoglobinopathies factors associated with hospital admission. Pediatr Emerg Care. 1995; 11(1):9-12.

DumapÉin CA, Avoiding admission for afebrile pediatric sickle cell pain: pain management methods J Pediatr Health Care. 2006; 20(2):115-22.

Schechter NL. The undertreatment of pain in chlidren an overview. Pediatr Clin North Am. 1989; 36(4) 781-94.

Shapiro BS. The management of pain in sickie cell disease, Pediatr Clin North Am. 1989; 36(4):1029-45.

Ballas SK. Current issues in sickle cell pain and Its management. Hematology. 2007; 97(1):97-105.

Friedchsdorf ST, Kang Tl. The management of pain in children with life-limtttng illnesses. Pediatr Clin North Am. 2007; 54(5):645-72.

Sorkin IS. Basic pharmacology and physiology of acute pain processing. Anesthesial Clin North Am, 1997; 15(2):235-49.

Walco GA, Dampier CD. Pain in children and adolescents with sickle cell disease: a descriptive study. J Pediatr Psychol. 1990; 15(5):643-58.

Gil KM. Coping with sickle cell disease pain. Ann Behav Med. 1989; 11(1):49-57.

Barakat LP, Schwartz LA, Simon K, Radcliffe J. Negative thinking as a coping strategy mediator of pain and internalizing symptoms in adolescents with sickle cell disease. J Behav Med. 2007; 30(3):199-208.

Walker DK, Jacobs FH. Cronically ill children in school. Peabody J Educ. 1984; 61 (2):29-71.

Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, ef al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991; 325(1):11-6.

Brown RT, Doepke KJ, Kaslow NJ. Risk-resistanceadaptation model for pediatric chronic ill-ness: sickle cell syndrome as an example. Clin Psychol Rev. 1993; 13(2): 119-32.

Finley AG. Frank LS, Grunau RE, von Baeyer CL. Why children's pain matters. Pain: Clin Updates. 2005; 12(4): 1-6.

Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Pediatr. 2008; 152(2):281-5.

Anand KJS. A fisiologia da dor em lactentes e crianças. In: A dor na infância. Nestlé Brasil. 2000; 59:1-9.

Berde C, Sethna NF. Anafgesics for the treatment of pain in children. N Engl J Med. 2002; 347(14):1094-103.

Jacobson SJ, Kopecky EA, Joshi P, Babu I N. Randomised trial of oral morphine for painful episodes of sickle- -cell disease in children. Lancet. 1997; 350(9088) 1358-61.

Newberger PF, Sallan SE, Chronic pain: principles of management. J Pediatr. 1981; 98(2):180-9.

Marlowue KF, Chicella MF. Treatment of sickle cell pain. Pharmacotherapy. 2002; 22(4):484-91.

Gel ler AK, O’Connor MK. The sickle cell crisis: a dilemma in pain relief. Mayo Clin Proc. 2008; 83(3):320-3.

Charache S. The treatment of sickfe cell anemia. Arch Intern Med. 1974; 133(4):698-705.

Steinberg MH. Drug therapy: Management of sickle cell disease. N Eng J Med. 1999; 340(13):1021-30.

Figueiredo MS. Situações de emergência. In: Agência Nacional de Vigilância Sanitária. Manual de diagnóstico e tratamento de doenças falciformes. Brasília Anvisa; 2002.

DE D. Sickle cell anaemia 2: management approaches of painful episodes. Br J Nurs. 2005; 14(9):484-9.

Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Management of vaso-occlusive pain in children with sickle cell disease. J Pediatr Hematol Oncol. 2003; 25(4):307-11.

Jacob E, Mueller BU, Pain experience of children with sickle cell disease who had prolonged hospitalizations for acute painful episodes. Pain Med, 2008; 9(1):13-21.

Chapman Jl, EL-Shammaa EN, Bonsu BK. The utility of screening laboratory studies in pediatric patients with sickle cell pain episodes. Am J Emerg Med. 2004; 22(4) :258-63.

Saad STO. Medidas gerais para o tratamento das doenças falciformes. In: Agência Nacional de Vigilância Sanitária. Manual de diagnóstico e tratamento de doenças falciformes. Brasília: Anvisa; 2002.

National Institute of Health. The management of sickle cell disease. Treatment of acute and chronic complications. Bethesda: NIH Publication; 2002. p.59-74.

Rees DC, OFujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of the acute painful crisis in sickle cell disease. Brit J Haematol. 2003; 120(5):744-52.

Centro de Educação e Apoio para Hemoglobinopatias Protocolo de atendimento aos eventos agudos da doença falciforme. Belo Horizonte: Fundação Hemominas; 2005.

Bricks LF, Silva C AA. Recomendações para o uso de anti-inflamatórios não hormonais em pediatria Pediatria. 2005; 27(2):114-25.

Hilário MO, Terreri MT, Len CA. Nonsteroidal antiinflamrnatory drugs: cyclooxygenase 2 inhibitors. J Pediatr. 2006; 82(5 Suppl):S206-12.

Wethers DL. Sickle cell disease in childhood: Part II Diagnosis and treatment of major complications and recent advances in treatment. Am Fam Physician 2000; 62(6): 1309-14.

Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwe ll M. Styles L. Quantification of analgesic use in children with sickle cell disease. Clin J Pain. 2007; 23(1):8-14.

Lobo C, Marra VN, Silva FIMG. Crises dolorosas na doença falciforme. Rev Bras Hernatol Hemoter. 2007

(3):247-58.

Ballas SK. Meperidine for acute sickle cell pain in the emergency department: revisited controvery. Ann Emerg Med. 2008; 51 (2):217.

Sociedade Brasileira para estudo da Dor. Disponível em: <http://www.dor.org.br/dor_diagnosticos.asp>.

Published

2009-02-28

How to Cite

Tostes, M. A., Braga, J. A. P., & Len, C. A. (2009). The painful vaso-occlusive crisis is the most common event and principal cause of sickle cell disease morbidity, as well as the most frequent reason for seeking emergency care and hospital admission. This study aimed to assess the índications, doses, administration routes and side effects of analgesics recommended to treat painful crises in children. A literature search was done in the Medline, SciELO, Lilacs and PubMed databases using the following keywords: anemia, sickle cell, analgesia. pain and child. Analysis of the literature reveafed that the treatment of painful crisis in children is complex, as it involves the subjectivity of pain, its correct measurement and its restrictíon to medication that is safe and efficient for use in the pediatric population, Treatment protocols exist as general guidelines, as conduct should always be individualized, Successful pain treatment depends on knowíedge of the pathophysiology of painful crisis, pharmacology of analgesics and valuing what the patient is feeling. Physicians should be ready to recognize and treat this complication which has a relevant impact on the quality of life of children with sickle cell disease. Revista De Ciências Médicas, 18(1). Retrieved from https://seer.sis.puc-campinas.edu.br/cienciasmedicas/article/view/653

Issue

Section

Atualização